Palvella Therapeutics, Inc. (NASDAQ:PVLA) Receives Consensus Recommendation of “Buy” from Analysts

Shares of Palvella Therapeutics, Inc. (NASDAQ:PVLA) have been assigned an average rating of “Buy” from the seventeen brokerages that are presently covering the company, MarketBeat reports. One investment analyst has rated the stock with a sell rating, fourteen have issued a buy rating and two have issued a strong buy rating on the company. The average 12 month price objective among brokers that have covered the stock in the last year is $158.6875.

A number of equities analysts have commented on PVLA shares. Weiss Ratings restated a “sell (d)” rating on shares of Palvella Therapeutics in a research report on Monday, December 29th. HC Wainwright set a $200.00 target price on Palvella Therapeutics and gave the stock a “buy” rating in a report on Monday, December 15th. Chardan Capital raised their price target on Palvella Therapeutics from $110.00 to $174.00 and gave the company a “buy” rating in a report on Monday, December 15th. BTIG Research reiterated a “buy” rating and issued a $192.00 price objective on shares of Palvella Therapeutics in a research report on Friday, January 16th. Finally, Stifel Nicolaus boosted their price objective on Palvella Therapeutics from $87.00 to $145.00 and gave the stock a “buy” rating in a research note on Monday, November 24th.

Insider Transactions at Palvella Therapeutics

In related news, COO Kathleen Goin sold 4,302 shares of the company’s stock in a transaction dated Wednesday, January 21st. The shares were sold at an average price of $97.63, for a total transaction of $420,004.26. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. In the last 90 days, insiders have sold 12,906 shares of company stock worth $1,205,980. 20.50% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Palvella Therapeutics

A number of institutional investors have recently modified their holdings of PVLA. Suvretta Capital Management LLC lifted its position in shares of Palvella Therapeutics by 15.1% during the third quarter. Suvretta Capital Management LLC now owns 822,400 shares of the company’s stock worth $51,556,000 after purchasing an additional 107,937 shares in the last quarter. Frazier Life Sciences Management L.P. lifted its holdings in Palvella Therapeutics by 4.7% during the 2nd quarter. Frazier Life Sciences Management L.P. now owns 722,400 shares of the company’s stock worth $16,283,000 after buying an additional 32,388 shares in the last quarter. First Light Asset Management LLC bought a new position in Palvella Therapeutics in the 3rd quarter valued at $33,949,000. Vanguard Group Inc. increased its stake in shares of Palvella Therapeutics by 202.0% in the 3rd quarter. Vanguard Group Inc. now owns 494,656 shares of the company’s stock valued at $31,010,000 after buying an additional 330,847 shares during the period. Finally, Federated Hermes Inc. acquired a new stake in shares of Palvella Therapeutics in the 3rd quarter valued at $21,255,000. 40.11% of the stock is owned by institutional investors.

Palvella Therapeutics Price Performance

Shares of NASDAQ:PVLA opened at $85.30 on Monday. The business’s fifty day moving average price is $97.37 and its two-hundred day moving average price is $71.01. Palvella Therapeutics has a fifty-two week low of $12.10 and a fifty-two week high of $114.69. The stock has a market capitalization of $1.01 billion, a price-to-earnings ratio of -32.43 and a beta of -0.16.

Palvella Therapeutics (NASDAQ:PVLA) last issued its quarterly earnings data on Monday, November 10th. The company reported ($1.03) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.85) by ($0.18). Research analysts expect that Palvella Therapeutics will post -3.69 EPS for the current fiscal year.

Palvella Therapeutics Company Profile

Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical‐stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small‐molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil‐ and complement‐mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella’s pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.